Atrion (NASDAQ:ATRI) Lifted to Sell at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a strong sell rating to a sell rating in a report published on Saturday, BidAskClub reports.

Separately, ValuEngine downgraded Atrion from a buy rating to a hold rating in a research note on Friday, July 26th.

Atrion stock opened at $754.29 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of 40.76 and a beta of 0.27. The stock has a 50 day moving average of $808.25. Atrion has a twelve month low of $624.00 and a twelve month high of $948.03.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $5.07 earnings per share for the quarter. The company had revenue of $41.61 million for the quarter. Atrion had a return on equity of 16.89% and a net margin of 22.76%.

In related news, Director Ronald Nicholas Spaulding sold 170 shares of the company’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $903.00, for a total value of $153,510.00. Following the sale, the director now owns 2,158 shares in the company, valued at approximately $1,948,674. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 22.07% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Kayne Anderson Rudnick Investment Management LLC boosted its stake in Atrion by 41.6% during the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 132,363 shares of the medical instruments supplier’s stock valued at $116,305,000 after purchasing an additional 38,912 shares during the last quarter. Pennsylvania Trust Co boosted its stake in Atrion by 441.3% during the 1st quarter. Pennsylvania Trust Co now owns 57,540 shares of the medical instruments supplier’s stock valued at $9,082,000 after purchasing an additional 46,911 shares during the last quarter. Geode Capital Management LLC boosted its stake in Atrion by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 17,922 shares of the medical instruments supplier’s stock valued at $13,281,000 after purchasing an additional 446 shares during the last quarter. KAMES CAPITAL plc boosted its stake in Atrion by 5.9% during the 2nd quarter. KAMES CAPITAL plc now owns 8,394 shares of the medical instruments supplier’s stock valued at $7,115,000 after purchasing an additional 470 shares during the last quarter. Finally, Martingale Asset Management L P boosted its stake in Atrion by 15.8% during the 1st quarter. Martingale Asset Management L P now owns 6,600 shares of the medical instruments supplier’s stock valued at $5,800,000 after purchasing an additional 900 shares during the last quarter. Institutional investors and hedge funds own 61.76% of the company’s stock.

Atrion Company Profile

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

See Also: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wells Fargo & Co  Expected to Post Quarterly Sales of $20.79 Billion
Wells Fargo & Co Expected to Post Quarterly Sales of $20.79 Billion
Zacks: Brokerages Expect Wells Fargo & Co  Will Post Earnings of $1.19 Per Share
Zacks: Brokerages Expect Wells Fargo & Co Will Post Earnings of $1.19 Per Share
$0.53 EPS Expected for Virtusa Co.  This Quarter
$0.53 EPS Expected for Virtusa Co. This Quarter
Zacks: Brokerages Anticipate Virtusa Co.  Will Post Quarterly Sales of $327.20 Million
Zacks: Brokerages Anticipate Virtusa Co. Will Post Quarterly Sales of $327.20 Million
Brokerages Anticipate United Natural Foods Inc  Will Post Earnings of $0.69 Per Share
Brokerages Anticipate United Natural Foods Inc Will Post Earnings of $0.69 Per Share
United Natural Foods Inc  Expected to Post Quarterly Sales of $6.44 Billion
United Natural Foods Inc Expected to Post Quarterly Sales of $6.44 Billion


© 2006-2019 Ticker Report